PA8597501A1 - Derivados azabiciclicos de piridiloximetilo y bencisoxazol - Google Patents

Derivados azabiciclicos de piridiloximetilo y bencisoxazol

Info

Publication number
PA8597501A1
PA8597501A1 PA20048597501A PA8597501A PA8597501A1 PA 8597501 A1 PA8597501 A1 PA 8597501A1 PA 20048597501 A PA20048597501 A PA 20048597501A PA 8597501 A PA8597501 A PA 8597501A PA 8597501 A1 PA8597501 A1 PA 8597501A1
Authority
PA
Panama
Prior art keywords
bencisoxazol
piridiloximetilo
azabiciclic
derivatives
azabicilical
Prior art date
Application number
PA20048597501A
Other languages
English (en)
Inventor
Gene Michael Bright
Michael Aaron Brodney
Bishop Wlodecki
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8597501A1 publication Critical patent/PA8597501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO AZABICILICO SUSTITUIDO DE AMINOMETILPIRIDILOXIMETILO/BENCISOXAZOL, UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL MISMO Y UN METODO PARA TRATAR UNO O MAS TRASTORNOS DEL CNS U OTROS, QUE INCLUYE EL TRATAMIENTO CONCURRENTE DE TRASTORNOS COMO ESQUIZOFRENIA Y DEPRESION.
PA20048597501A 2003-03-12 2004-03-08 Derivados azabiciclicos de piridiloximetilo y bencisoxazol PA8597501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45392503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
PA8597501A1 true PA8597501A1 (es) 2005-05-24

Family

ID=32990837

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048597501A PA8597501A1 (es) 2003-03-12 2004-03-08 Derivados azabiciclicos de piridiloximetilo y bencisoxazol

Country Status (31)

Country Link
US (1) US7345038B2 (es)
EP (1) EP1608648B1 (es)
JP (2) JP3910627B2 (es)
KR (2) KR100767854B1 (es)
CN (1) CN100389115C (es)
AP (1) AP2005003390A0 (es)
AR (1) AR043537A1 (es)
AU (2) AU2004220327B2 (es)
BR (1) BRPI0408248A (es)
CA (1) CA2518740C (es)
EA (1) EA009527B1 (es)
EC (1) ECSP056011A (es)
GT (1) GT200400041A (es)
HK (1) HK1085725A1 (es)
HR (1) HRP20050798A2 (es)
IL (1) IL170290A (es)
MA (1) MA27747A1 (es)
MX (1) MXPA05009660A (es)
NL (1) NL1025710C2 (es)
NO (1) NO20054095L (es)
OA (1) OA13038A (es)
PA (1) PA8597501A1 (es)
PE (1) PE20041057A1 (es)
PL (1) PL378749A1 (es)
RS (1) RS20050692A (es)
TN (1) TNSN05224A1 (es)
TW (1) TW200502234A (es)
UA (1) UA78437C2 (es)
UY (1) UY28225A1 (es)
WO (1) WO2004081007A1 (es)
ZA (1) ZA200506373B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
JP4916883B2 (ja) * 2003-10-15 2012-04-18 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
CA2555172A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1791540A2 (en) * 2004-09-10 2007-06-06 Pfizer Products Incorporated Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2012052540A1 (en) * 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2016115282A1 (en) * 2015-01-13 2016-07-21 Vanderbilt University Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2023083445A1 (en) 2021-11-10 2023-05-19 Symrise Ag Compositions comprising trpm8 agonistic cooling agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
US5167034A (en) * 1990-06-18 1992-11-24 International Business Machines Corporation Data integrity for compaction devices
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
JPH08827B2 (ja) 1991-09-25 1996-01-10 フアイザー・インコーポレイテツド 精神弛緩剤の２−置換パーヒドロ−１Ｈ−ピリド［１，２−ａピラジン
JP2753146B2 (ja) 1992-06-16 1998-05-18 ファイザー・インコーポレーテッド ビス−アザー二環式抗不安薬の製法および中間体
WO1996010570A1 (en) 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
AU745964B2 (en) 1997-05-30 2002-04-11 Neurosearch A/S 8-Azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
PL346248A1 (en) 1998-08-26 2002-01-28 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
NZ510587A (en) 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
BR9913887A (pt) 1998-09-18 2001-10-23 Basf Ag Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
IL144897A0 (en) 1999-03-12 2002-06-30 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders

Also Published As

Publication number Publication date
JP3910627B2 (ja) 2007-04-25
NL1025710C2 (nl) 2005-10-10
UY28225A1 (es) 2004-11-08
US20050026922A1 (en) 2005-02-03
HK1085725A1 (en) 2006-09-01
EA009527B1 (ru) 2008-02-28
GT200400041A (es) 2005-03-23
MA27747A1 (fr) 2006-02-01
MXPA05009660A (es) 2005-10-20
US7345038B2 (en) 2008-03-18
TNSN05224A1 (fr) 2007-06-11
JP2006519830A (ja) 2006-08-31
WO2004081007A1 (en) 2004-09-23
NO20054095D0 (no) 2005-09-02
UA78437C2 (en) 2007-03-15
ZA200506373B (en) 2006-10-25
OA13038A (en) 2006-11-10
NL1025710A1 (nl) 2004-09-14
KR20070074667A (ko) 2007-07-12
IL170290A (en) 2011-02-28
AU2004220327A1 (en) 2004-09-23
CA2518740A1 (en) 2004-09-23
CA2518740C (en) 2011-01-11
EP1608648A1 (en) 2005-12-28
RS20050692A (en) 2007-11-15
CN100389115C (zh) 2008-05-21
PL378749A1 (pl) 2006-05-15
AU2004220327B2 (en) 2010-06-24
BRPI0408248A (pt) 2006-03-01
CN1759116A (zh) 2006-04-12
JP2007051155A (ja) 2007-03-01
HRP20050798A2 (en) 2006-02-28
TW200502234A (en) 2005-01-16
KR20050113221A (ko) 2005-12-01
AP2005003390A0 (en) 2005-09-30
NO20054095L (no) 2005-09-26
PE20041057A1 (es) 2005-01-22
EP1608648B1 (en) 2012-07-18
KR100767854B1 (ko) 2007-10-17
ECSP056011A (es) 2006-01-27
AU2010203303A1 (en) 2010-08-12
EA200501148A1 (ru) 2006-04-28
AR043537A1 (es) 2005-08-03

Similar Documents

Publication Publication Date Title
ECSP056011A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
BR112017017610A2 (pt) composto, composição farmacêutica, método de tratamento, método de diagnóstico, método de modulação da atividade
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
CL2008003486A1 (es) 6-oxo-1,6-dihidropiridazinas; sus usos para tratar un trastorno hiperproliferativo; la composición farmacéutica que las contiene; y sus procesos de preparación (div. sol. 1168-06).
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BRPI0507250A (pt) combinações para tratar desordens do snc
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
ECSP21026021A (es) Moduladores de la expresión de pnpla3
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
AR047759A1 (es) Derivados de fenil - piperazina como moduladores de receptores muscarnicos
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
UY28925A1 (es) Nuevos derivados de aminopiridina y su uso como fármacos
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
MX2022014220A (es) Inhibidores de calmodulin, inhibidores de chk2 e inhibidores de rsk para el tratamiento de trastornos ribosomales y ribosomatopias.
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
CL2020000586A1 (es) Moduladores de la expresión de enac.